10 Stocks Under $10 that Will Triple

8. Vir Biotechnology, Inc. (NASDAQ:VIR)

Upside Potential: 413.24%

Number Of Hedge Funds: 31

Vir Biotechnology, Inc. (NASDAQ:VIR) develops treatments for infectious diseases and cancer. The company uses the body’s immune system to fight diseases like solid tumors. It is working on experimental therapies targeting cancer cells precisely and developing PRO-XTEN technology to make cancer treatments safer and more efficient.

Despite revenue declines, Vir Biotechnology, Inc. (NASDAQ:VIR) showed operational improvements for Q4 and FY24. Q4 revenue was $12.4 million, down from $16.8 million a year earlier, whereas full-year revenue fell to $74.2 million from $86.2 million. The decline came from lower grant revenue and reduced profit-sharing under the GSK Agreement. At the same time, expenses dropped to $506.5 million for 2024 due to discontinued programs, though this was partly offset by a $102.8 million upfront payment to Sanofi. Likewise, General and Administrative expenses fell to $119.0 million from $174.4 million thanks to cost-saving efforts.

On the other hand, Vir Biotechnology, Inc. (NASDAQ:VIR) ended 2024 with $1.10 billion in cash and cash equivalents and investments, down $532.3 million over the year, mainly from strategic investments like the Sanofi licensing deal. Still, the company’s financial position remains strong, with cash projected to last into mid-2027.

Looking ahead, Vir Biotechnology, Inc. (NASDAQ:VIR) is advancing its immuno-oncology pipeline while simultaneously expanding into infectious diseases, as the company enrolled its first patient in the Phase 3 ECLIPSE program for chronic Hepatitis Delta. This strengthens the company’s late-stage portfolio and builds investor confidence.

As such, analysts see high upside potential for the stock based on its existing pipeline and partnerships, which have attracted hedge funds that are looking for long-term growth. Thus, Vir Biotechnology, Inc. (NASDAQ:VIR) is considered one of the stocks that will triple.